The American Society of Clinical Oncology’s (ASCO) annual meeting for 2018 is to be held at McCormick Place in Chicago from June 1 to 5. Oncology’s leading specialists and academics from around the world will gather together to network and discuss the most recent achievements globally in cutting-edge clinical oncology research and therapeutic technologies targeting cancer.
In response to the meeting’s theme—“Delivering Discoveries: Expanding the Reach of Precision Medicine”—more than 2,500 abstracts from around the world have been submitted for the annual event, together with an enormous variety of posters and verbal reports. The meeting will consist of workshops, keynote speeches and more, which will address both basic and clinical medical sciences.
Abstracts from ten of Genecast’s programs highlighting achievements in these areas have been selected for publishing on the meeting’s online portal. Genecast’s inclusion on this internationally renowned academic platform is thanks to its unique “clinically oriented cooperation and innovation” model as well as to the solid strength in scientific research that it has accumulated over the past four years.
Comparative genomic profiling of distant metastatic and nondistant metastatic lung adenocarcinoma
PD-L1 expression and TMB status in newly diagnosed metastatic non-small cell lung cancer and their effect on prognosis after EGFR-TKI or platinum-based chemotherapy
PD-L1 expression of 742 newly diagnosed advanced respiratory and digestive system tumours in China based on SP142 assay
The mutational landscape of circulating cell free DNA in patients with colorectal adenoma and carcinoma
The mutational landscape of circulating cell free DNA in patients with esophageal squamous cell carcinoma response and non-response to neoadjuvant chemotherapy
Early recurrence detected in HCC patients after TACE treatment with plasma cfDNA
EGFR and ERBB2 could potentially determine the metastatic status of mediastinal lymph nodes in lung adenocarcinomas harbouring EGFR mutation
Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers
Comprehensive genomic profiling of gastric cancer to reveal distinctive genomic alterations between peritoneal metastasis (PM) patients (pts) and non-PM pts.
Establishment of a prediction model for the clinical efficacy of chemotherapy in small cell lung cancer